Accor : Résultats S1 18 (26/07 avant Bourse) : solide tendance de RevPAR, la guidance d’EBITDA 2018 pourrait amener de légers ajustements
>Résultats S1 2018 tirés par une croissance de 5%e de RevPAR - AccorHotels publiera ses résultats S1 2018 le 26/07 avant Bourse. Nous attendons une solide tendance de RevPAR au S1, à +5.0%e soit +4.6%e au T2 suggérant un léger ralentissement (+5.3% au T1) principalement lié à l’Amérique du Sud (+4.0%e au T2 vs +13.9% au T1). Par marché au S1, nous anticipons une dynamique toujours bonne en France (22% de l’EBIT) et en Europe à +4.8%e (dont +5.0%e au T2), ainsi qu’en A...Shenzhen Accord Pharmaceutical is engaged in the research, development and production of pharmaceuticals; and wholesales and chain retails of Chinese and western patent medicine, Chinese traditional medicine, biological products, bio-chemical medicine, health care products and medical apparatus and instruments. Through its subsidiaries, Co. is also engaged in the manufacture of raw material for chemical medicine, processing of Chinese patent drugs and medical chemical raw materials; sale of antibiotic preparations, chemical reagent and Chinese medical crop; and provision of logistic and storage services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.